23andMe’s Former CEO Pushes Purchase Price Nearly $50 Million Higher

by | June 5, 2025 8:09 am | US Markets

23andMe has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing company’s former chief executive pushed a bankruptcy court to reopen its sale process.